NASDAQ:MDWD MediWound Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MediWound Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $1.79 -0.05 (-2.72%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$1.78▼$1.8550-Day Range$1.33▼$2.2552-Week Range$1.21▼$4.95Volume40,256 shsAverage Volume112,676 shsMarket Capitalization$59.32 millionP/E RatioN/ADividend YieldN/APrice Target$7.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media MediWound Stock Forecast (MarketRank)Analyst RatingBuy3.00 Rating ScoreUpside/Downside300.4% Upside$7.17 Price TargetShort InterestHealthy0.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.82Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.38) to ($0.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.60 out of 5 starsMedical Sector914th out of 1,429 stocksMedicinals & Botanicals Industry7th out of 23 stocks 3.5 Analyst's Opinion Consensus RatingMediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.17, MediWound has a forecasted upside of 300.4% from its current price of $1.79.Amount of Analyst CoverageMediWound has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.18% of the float of MediWound has been sold short.Short Interest Ratio / Days to CoverMediWound has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MediWound has recently decreased by 45.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMediWound does not currently pay a dividend.Dividend GrowthMediWound does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MDWD. Previous Next 2.1 News and Social Media Coverage News SentimentMediWound has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for MediWound this week, compared to 2 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediWound insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 13.58% of the stock of MediWound is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MediWound are expected to grow in the coming year, from ($0.38) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediWound is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediWound is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MDWD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter. Email Address About MediWound (NASDAQ:MDWD)MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.Read More MDWD Stock News HeadlinesJuly 1, 2022 | streetinsider.comForm SC 13D/A MediWound Ltd. Filed by: Access Industries Holdings LLC - StreetInsider.comJune 30, 2022 | finance.yahoo.comMediWound Names Mr. Tzvi Palash as Chief Operating Officer - Yahoo FinanceJune 30, 2022 | globenewswire.comMediWound Names Mr. Tzvi Palash as Chief Operating Officer - GlobeNewswireJune 30, 2022 | finance.yahoo.comMediWound Names Mr. Tzvi Palash as Chief Operating OfficerJune 24, 2022 | americanbankingnews.comMediWound (NASDAQ:MDWD) Coverage Initiated at StockNews.comJune 20, 2022 | globenewswire.comAsia Pacific Wound Care Biologics Market to Surpass US$ 533.8 Million by 2030, Says Coherent Market Insights (CMI) - GlobeNewswireJune 15, 2022 | americanbankingnews.comMediWound (NASDAQ:MDWD) Receives New Coverage from Analysts at StockNews.comJune 11, 2022 | finance.yahoo.comGamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors - Yahoo FinanceJune 10, 2022 | streetinsider.comForm 8-K Gamida Cell Ltd. For: Jun 08 - StreetInsider.comJune 10, 2022 | businesswire.comGamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors - Business WireJune 9, 2022 | streetinsider.comForm 6-K MediWound Ltd. For: Jun 09 - StreetInsider.comMay 19, 2022 | finance.yahoo.comIs MediWound (NASDAQ:MDWD) In A Good Position To Deliver On Growth Plans?May 17, 2022 | nasdaq.comHealth Care Sector Update for 05/17/2022: TEVA,NAOV,MDWD - NasdaqSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MDWD CUSIPN/A CIK1593984 Webwww.mediwound.com Phone972779714100Fax972-77-971-4111Employees77Year FoundedN/ACompany Calendar Last Earnings5/17/2022Today7/01/2022Next Earnings (Estimated)8/09/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$7.17 High Stock Price Forecast$8.00 Low Stock Price Forecast$6.50 Forecasted Upside/Downside+300.4%Consensus RatingBuy Rating Score (0-4)3 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13.55 million Net Margins-64.01% Pretax Margin-63.87% Return on Equity-3,540.43% Return on Assets-59.86% Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick Ratio1.78 Sales & Book Value Annual Sales$23.76 million Price / Sales2.50 Cash FlowN/A Price / Cash FlowN/A Book Value($0.17) per share Price / Book-10.53Miscellaneous Outstanding Shares33,141,000Free FloatN/AMarket Cap$59.32 million OptionableNot Optionable Beta1.25 MediWound Frequently Asked Questions Should I buy or sell MediWound stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MediWound stock. View analyst ratings for MediWound or view top-rated stocks. What is MediWound's stock price forecast for 2022? 3 Wall Street analysts have issued 1-year target prices for MediWound's shares. Their MDWD stock forecasts range from $6.50 to $8.00. On average, they expect MediWound's share price to reach $7.17 in the next twelve months. This suggests a possible upside of 300.4% from the stock's current price. View analysts' price targets for MediWound or view top-rated stocks among Wall Street analysts. How has MediWound's stock price performed in 2022? MediWound's stock was trading at $2.36 at the beginning of 2022. Since then, MDWD shares have decreased by 24.2% and is now trading at $1.79. View the best growth stocks for 2022 here. When is MediWound's next earnings date? MediWound is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for MediWound. How were MediWound's earnings last quarter? MediWound Ltd. (NASDAQ:MDWD) posted its quarterly earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. The biopharmaceutical company had revenue of $4.41 million for the quarter, compared to analysts' expectations of $4.35 million. MediWound had a negative trailing twelve-month return on equity of 3,540.43% and a negative net margin of 64.01%. During the same period last year, the business earned ($0.10) EPS. View MediWound's earnings history. Who are MediWound's key executives? MediWound's management team includes the following people: Mr. Sharon Malka CPA, MBA, Chief Exec. Officer (Age 50, Pay $497k)Prof. Lior Rosenberg M.D., Co-Founder & Chief Medical Technology Officer (Age 76, Pay $398k)Mr. Boaz Gur-Lavie CPA, M.B.A., Chief Financial Officer (Age 48, Pay $309k)Mr. Yaron Meyer Adv., Exec. VP, Gen. Counsel & Corp. Sec. (Age 43, Pay $240k)Dr. Ety Klinger, Chief R&D Officer (Age 60, Pay $344k)Mr. Stephen T. Wills CPA, CPA, MST, Exec. Chairman (Age 65) Who are some of MediWound's key competitors? Some companies that are related to MediWound include MariMed (MRMD), biote (BTMD), Exactus (EXDI), ChromaDex (CDXC), HEXO (HEXO), Grove (GRVI), Natural Alternatives International (NAII), FitLife Brands (FTLF), IM Cannabis (IMCC), Mannatech (MTEX), Charlie's (CHUC), Bon Natural Life (BON), Charlie's (CHUCD), Smart for Life (SMFL) and Heyu Biological Technology (HYBT). View all of MDWD's competitors. What other stocks do shareholders of MediWound own? Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo (WFC). What is MediWound's stock symbol? MediWound trades on the NASDAQ under the ticker symbol "MDWD." How do I buy shares of MediWound? Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MediWound's stock price today? One share of MDWD stock can currently be purchased for approximately $1.79. How much money does MediWound make? MediWound (NASDAQ:MDWD) has a market capitalization of $59.32 million and generates $23.76 million in revenue each year. The biopharmaceutical company earns $-13.55 million in net income (profit) each year or ($0.51) on an earnings per share basis. How many employees does MediWound have? MediWound employs 77 workers across the globe. How can I contact MediWound? MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The official website for MediWound is www.mediwound.com. The biopharmaceutical company can be reached via phone at 972779714100, via email at [email protected], or via fax at 972-77-971-4111. This page (NASDAQ:MDWD) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
